Skip to content
Triangle logo TriangleGet started
← Study library

NCT04925193 · REGISTRY CONDITION SEARCH

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-04-07

Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by physician's choice and compared prospectively to ex vivo drug sensitivity testing results. Participants will be enrolled and assigned into one of three treatment selection groups. The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually. Selection groups are as follows: Group 1: Selinexor + pomalidomide + dexamethasone (SPd) Group 2: Selinexor + daratumumab + dexamethasone (SDd) Group 3: Selinexor + carfilzomib + dexamethasone (SKd)

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

MRD Negative Response Rate

→

outcome · POSTED

Progression Free Survival

→

outcome · NOT POSTED

Overall Survival

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Time to Next Treatment

→

outcome · POSTED

Safety and Tolerability of Selinexor in Combination With Partner Backbone Agents

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure. 3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 4. Histologically confirmed diagnosis, measurable disease and evidence of disease progression of MM after 1 or more prior lines of therapy with either of: 1. Documented evidence of PD after achieving at least SD for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM) 2. ≤ 25% response (i.e, patient never achieved ≥ MR) or PD during or within 60 days from end of the most recent MM regimen (i.e., refractory MM) 5. Patients must have measurable disease as defined by at least one of the following: a) Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative IgA c) Urinary M-protein excretion at least 200 mg/24 hours d) Serum FLC ≥ 10 mg/dL, provided that FLC ratio is abnormal e) If no measurable disease by serum or urine, then the presence of a plasmacytoma of ≥ 2cm in one dimension prior to start of study can be used to follow response via radiologic imaging 6. Adequate hepatic function: f) Total bilirubin \<1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \<3 × ULN), and g) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<2.5 × ULN. 7. Adequate renal function as determined by serum creatinine of ≤ 2 mg/dL OR estimated creatinine clearance of ≥ 20 mL/min, calculated using the Cockcroft and Gault formula (140 - Age) • Mass (kg)/ (72 • creatinine mg/dL); multiply by 0.85 if female. 8. Adequate hematopoietic function within 28 days prior to C1D1: absolute neutrophil count ≥1000/mm3, hemoglobin ≥8 g/dL and platelet count ≥100,000/mm3 (patients for whom \<50% of bone marrow nucleated cells are plasma cells) or ≥50,000/mm3 (patients for whom ≥50% of bone marrow nucleated cells are plasma cells). 1. Patients may receive hematopoietic growth factor support, including erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (eg, eltrombopag, romiplostim, or interleukin-11) at any time 2. Patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study. 9. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 3 months following the last dose of protocol required therapies. Exclusion Criteria: 1. Has received selinexor or another XPO1 inhibitor in a previous line of therapy 2. Has any concurrent medical condition or disease (eg, uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures. 3. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to Cycle 1 Day 1 (C1D1). Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable. 4. Known intolerance, hypersensitivity, or contraindication to glucocorticoids. 5. Pregnant or breastfeeding females. 6. Major surgery within 4 weeks prior to C1D1. 7. Active, unstable cardiovascular function, as indicated by the presence of: 1. Symptomatic ischemia, or 2. Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or 3. Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction \<40%, or 4. Myocardial infarction within 3 months prior to C1D1. 8. Subjects with active hepatitis B virus (Hep B) are allowed if antiviral therapy for hepatitis B has been given for \>8 weeks and viral load is \<100 IU/ml prior to first dose of trial treatment. Subjects with untreated hepatitis C virus (HCV) are allowed. Subjects with Human Immunodeficiency Virus (HIV) who have CD4+ T-cell counts ≥ 350 cells/µL and no history of AIDS- defining opportunistic infections in the last year are allowed. 9. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment, including prior gastric bypass or bowel resection procedures. 10. Inability or unwillingness to take supportive medications such as anti-nausea and anti anorexia agents as recommended by the NCCN CPGO for antiemesis and anorexia/cachexia (palliative care). 11. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent. 12. Contraindication to any of the required concomitant drugs or supportive treatments. 13. Patients unwilling or unable to comply with the protocol, including providing 24-hour urine samples for urine protein electrophoresis at the required time points.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Treatment Options: Selinexor 60 mg PO days 1, 8, 15 Pomalidomide 4 mg PO on days 1-21 Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22 28 day treatment cycles Selinexor 80 mg PO days 1, 8, 15 Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles \>6 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 28 day treatment cycle Selinexor 80 mg PO days 1, 8, 15 Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15. Dexamethasone 40 mg IV or PO days 1, 8, 15, 22 28 day treatment cycle
    intervention Names
    1. Drug: Selinexor
    2. Drug: Pomalidomide
    3. Drug: Daratumumab
    4. Drug: Carfilzomib
    5. Drug: Dexamethasone
    label
    Arm 1
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm 1
    description
    Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).
    name
    Selinexor
    type
    DRUG
  2. arm Group Labels
    1. Arm 1
    description
    Oral Table
    name
    Pomalidomide
    type
    DRUG
  3. arm Group Labels
    1. Arm 1
    description
    Injection
    name
    Daratumumab
    type
    DRUG
  4. arm Group Labels
    1. Arm 1
    description
    Injection
    name
    Carfilzomib
    type
    DRUG
  5. arm Group Labels
    1. Arm 1
    description
    Oral tablet or injection
    name
    Dexamethasone
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
intervention Model Description
The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually.
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
18
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    To evaluate the overall response rate achieved with physician's choice selinexor-based combination therapy as measured by International Myeloma Working Group criteria (based on Kumar et al 2016).
    measure
    Overall Response Rate
    time Frame
    End of Therapy, on average 10 months
secondary Outcomes
  1. description
    To evaluate the minimal residual disease negative response rate achieved with physician's choice selinexor-based combination therapy assessed via NGS or multiparametric flow cytometry with sensitivity of 10-5.
    measure
    MRD Negative Response Rate
    time Frame
    2 years following End of Treatment or date of progression (whichever comes first), assessed up to 2 years
  2. description
    To evaluate the duration of progression free survival achieved with physician's choice selinexor-based combination therapy
    measure
    Progression Free Survival
    time Frame
    End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years
  3. description
    To evaluate the duration of overall survival achieved with physician's choice selinexor-based combination therapy.
    measure
    Overall Survival
    time Frame
    EOT + 2 years, or date of progression (whichever comes first)
  4. description
    To evaluate the duration of response achieved with physician's choice selinexor-based combination therapy
    measure
    Duration of Response
    time Frame
    End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years
  5. description
    To evaluate the time to next treatment achieved with physician's choice selinexor-based combination therapy
    measure
    Time to Next Treatment
    time Frame
    End of Treatment +2 years, or date of progression (whichever comes first), assessed up to 2 years
  6. description
    Occurrence, nature, and severity of adverse events
    measure
    Safety and Tolerability of Selinexor in Combination With Partner Backbone Agents
    time Frame
    From first dose of study drug through 30 days after last dose of protocol required therapies
Full study description
brief Summary
Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by physician's choice and compared prospectively to ex vivo drug sensitivity testing results. Participants will be enrolled and assigned into one of three treatment selection groups. The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually. Selection groups are as follows: Group 1: Selinexor + pomalidomide + dexamethasone (SPd) Group 2: Selinexor + daratumumab + dexamethasone (SDd) Group 3: Selinexor + carfilzomib + dexamethasone (SKd)
detailed Description
This study is a single institution, open-label phase II study to evaluate the overall response rate achieved with selinexor and dexamethasone based three drug combination therapy, selected by physician's choice, in patients with relapsed/refractory multiple myeloma. Patients with RRMM will be eligible for enrollment. During screening, in addition to standard of care disease assessments, participant's bone marrow aspirate will be evaluated using a novel ex vivo Myeloma Drug Sensitivity Testing platform (My-DST). The following agents will be eligible for physician's choice, and in parallel evaluated for sample sensitivity in MyDST: pomalidomide, carfilzomib and daratumumab. Agents will be tested individually, in combination with selinexor and in combination with selinexor and dexamethasone. Results from MyDST will be not be available to investigators at time of treatment assignment, but will be evaluated to better characterize test performance and relationship with treatment outcomes. Investigators will assign patients to one of the following treatment combinations: Selinexor/Pomalidomide/Dexamethsone (SPd), Selinexor/Daratumumab/Dexamethasone (SDd) or Selinexor/Carfilzomib/Dexamethasone (SKd). Investigators will use patient specific considerations such as prior therapeutic exposures, response to / tolerance of prior therapies and comorbid conditions which may increase risk for toxicity with specific agents to guide expert judgement in selecting partner agent for selinexor and dexamethasone. Treatment will continue until progression of disease, unacceptable toxicity or death. This study will evaluate if physician's choice partner drug selection for selinexor based combination therapy in RRMM will lead to an overall response rate of 75% or higher.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-a6d6eb7ba28ce248ee30
      requested nct id
      NCT04925193
      primary nct id
      NCT04925193
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      1a948edd57ab8a8a42163e9d185be58ad6b056e352e1d47b83c8b22a78bb27a4
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-a6d6eb7ba28ce248ee30
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT04925193
      occurrences
      1. context exact
        NCT04925193
        end
        11
        exact text
        NCT04925193
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/892/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      168a57531123998530c47584a65bc07b3ca3509ae34d9507157e997b21aaae07

    Preserved source evidence · Not medical advice